To evaluate infection outcomes and serological response following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 vaccines in kidney and kidney pancreas transplants
Latest Information Update: 17 Mar 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 17 Mar 2022 New trial record
- 08 Mar 2022 Results published in the Transplantation